Recent Updates — PRCT
PROCEPT BioRobotics reported third-quarter 2026 total revenue of $98.3 million, an 18% increase from the prior year period, driven by a 21% rise in U.S. handpiece and consumable sales to $53.9 million and a 32% jump in international revenue to $12.5 million. The company performed over 13,400 U.S. procedures, reflecting 22% growth, while delivering 62 HYDROS systems with an average selling price of approximately $495,000. Gross margin improved slightly to 66%, though the net loss widened to $26.5 million from $21.4 million a year earlier as operating expenses rose to $92.5 million due to continued investment in product development and sales. The company reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and reiterated an adjusted EBITDA loss range of $30 million to $35 million. PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
On October 2, 2026, the Board of Directors of PROCEPT BioRobotics Corporation approved an increase in board size from nine to ten members. The company appointed Dr. Michael Mack as a new Class II director to fill the vacancy, effective immediately. His term expires at the 2029 annual meeting. Dr. Mack is an independent cardiac surgeon with extensive leadership experience in thoracic surgery and medical research institutions. He will receive compensation consistent with other non-employee directors. PROCEPT BioRobotics Corporation operates in the medical device industry, developing robotic-assisted surgical systems for urology and gynecology.
On September 23, 2026, PROCEPT BioRobotics Corporation entered into a Third Amendment to its Loan and Security Agreement with Canadian Imperial Bank of Commerce. The amendment extends the Term Loan Maturity Date by twelve months, moving it from October 1, 2027, to October 1, 2028. All other terms, including affirmative and negative covenants, remain unchanged. This modification provides the company with additional time to repay its debt obligations without altering the fundamental structure of the existing credit facility. PROCEPT BioRobotics Corporation operates in the medical device industry, specializing in robotic-assisted urological surgery.
PROCEPT BioRobotics reported second quarter 2026 financial results with total revenue of $94.5 million, a 19% increase year-over-year. U.S. procedures exceeded 13,100, up approximately 21%, and the company delivered 65 HYDROS systems in the U.S., including 14 replacements, at an average selling price of roughly $495,000 per new system. Gross margin improved to 66% from 65% in the prior year period, aided by a $2.9 million tariff refund and increased pricing. Operating expenses rose to $89.8 million compared to $73.9 million previously, driven by commercial investments and clinical trial costs for the WATER IV study. The company reported a net loss of $26.9 million versus a $19.6 million loss in the prior year period. Full-year 2026 revenue guidance remains unchanged at $390 million to $410 million, while adjusted EBITDA loss expectations were widened to $35 million–$30 million from previous estimates. PROCEPT BioRobotics operates in the surgical robotics industry, developing AI-powered robotic systems and Aquablation therapy for treating benign prostatic hyperplasia.